Rachel B. Wagman
Chief Clinical AdvisorDr. Rachel B. Wagman is Chief Clinical Advisor of Entera Bio Ltd. from May 15, 2024. Dr. Wagman joined the Entera Bio Ltd. on May 15, 2024. Dr. Wagman brings many years of metabolic bone disease and women's health research and drug development experience to Entera. She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo), denosumab (Prolia) and romosozumab (Evenity) through clinical development, registration and lifecycle management. President, Clinical Development, she integrated Myovant's development portfolio into the newly-established Sumitomo Pharma America. She completed her BA at the University of Pennsylvania, MD at Jefferson Medical College, Internal Medicine residency at Thomas Jefferson University Hospital and postdoctoral fellowship in Endocrinology, Gerontology and Metabolism at Stanford University School of Medicine. She is a Fellow of both the American College of Endocrinology and the American College of Physicians and holds dual board certifications in Internal Medicine and Endocrinology, Diabetes and Metabolism.
Positions
- Company NameEntera Bio Ltd.Stock CodeENTXPositionChief Clinical AdvisorColleagues
- MJMiranda J. ToledanoCEO & Director
- GJGeno J. GermanoIndependent Chairman
- HGHillel GalitzerChief Operating Officer
- GBGregory BurshteinChief of Research & Development
- DYDana Yaacov-GarbeliChief Financial Officer
- FCFelicia CosmanChairman of Scientific Advisory Board & Chief Clinical Advisor (Endocrinology)
- HTHaya TaitelNon-Employee Independent Director
- SDSteven D. RubinIndependent Director
